Sage Therapeutics (SAGE) Q3 Earnings call transcript Oct 29, 2024
2min read In Sage Therapeutics' third quarter 2024 earnings call, management provided updates on the company's financial performance, business operations, and strategic initiatives. The call was marked by a focus on the company's flagship product, Zurzuvae, and its role in transforming the treatment paradigm for postpartum depression (PPD). Here are the key takeaways from the call:
Financial Performance:Sage Therapeutics reported a net loss of $93.6 million in the third quarter of 2024. However, the company's revenue for the quarter was $11 million, driven by collaboration revenue from the sales of Zurzuvae. The company also announced a reorganization of its business operations, which includes the discontinuation of ZULRESSO commercialization after December 31, 2024, and a strategic decision to stop further development of zuranolone as a treatment for major depressive disorder in the U.S.
Zurzuvae and PPD:Zurzuvae, the company's lead product, has shown significant growth, with total revenue of $22.1 million in the third quarter of 2024. The product is being well-received in the market, with approximately 2,000 prescriptions filled and delivered to women with PPD. Sage Therapeutics aims to establish Zurzuvae as the first line therapy and standard of care for women with PPD, with a focus on expanding the prescriber base and increasing repeat prescriptions.
Pipeline and Development:Sage Therapeutics also provided updates on its pipeline, including the ongoing Phase II DIMENSION study of dalzanemdor in people with cognitive impairment associated with Huntington's disease. The company also announced the termination of its collaboration and license agreement with Biogen for the SAGE-324 program, with plans to evaluate potential indications for the program in the future.
Strategic Focus:The call highlighted Sage Therapeutics' strategic focus on PPD, with plans to accelerate the growth of Zurzuvae through field force expansion, targeted media campaigns, and a focus on supporting repeat writing in PPD. The company also emphasized its commitment to advancing brain health medicines and creating long-term value for shareholders.
Challenges and Opportunities:Despite setbacks, including the failure of the Phase II LIGHTWAVE study in Alzheimer's disease and the termination of the collaboration with Biogen, Sage Therapeutics remains optimistic about its future. The company is reorganizing to strengthen its balance sheet and focus resources on the ongoing launch of Zurzuvae and the upcoming readout in Huntington's disease.
Investor and Analyst Questions:During the Q&A session, analysts asked about script trends from the sales force expansion, the potential impact of telehealth on PPD treatment, and the details around the decision to not pursue MDD. Management provided insightful responses, highlighting the company's strategic focus on PPD and its commitment to driving growth through targeted commercialization efforts.
Conclusion:Sage Therapeutics' third quarter 2024 earnings call underscored the company's continued progress in transforming the treatment landscape for PPD with Zurzuvae. Despite challenges, Sage Therapeutics remains focused on its strategic priorities, with a clear vision for growth and value creation. The company's commitment to advancing brain health medicines and creating a positive impact on patient lives is a testament to its dedication to innovation and progress in the field of mental health.
_56ef5cf71747658846645.jpeg)
Recover Your Lost Funds with Expert Assistance from BSB Forensic
If you've fallen victim to fraudulent activities involving a company, broker, or account manager, don't lose hope. BSB Forensic specializes in helping individuals recover lost funds through thorough investigation and expert financial recovery strategies.
I personally recommend their trusted services—they successfully assisted me in recovering my lost funds, and I am confident they can help you too.
For more information and to start your recovery process today, visit Bsbforensic. com
yes
If you ever want to change or up your university grades, contact Cybergolden Hacker; he'll get it done and show proof of work done before payment. He's efficient, reliable, and affordable. He can also perform all sorts of hacks, including text, WhatsApp, password decryption, hacking any mobile phone, escaping bankruptcy, deleting criminal records, and the rest.
Email: cybergoldenhacker at gmail dot com
We made contac! The Ancient Alien Theorists were right!
No recent comments, so I'll update things. As of writing this, BoxOfficeMojo is reporting Sinners has reached $236,728,722 worldwide in 17 days. Word of mouth helped it to hardly drop off much, even in third weekend against the opening of Thunderbolts. So it should end up probably over $300 mil before done, not counting home video profits.
A bonified smash!
*finger crossed* It gets some love at the Oscars.
I'd recommen holding everyone like look at what it was December 2024 I think it was wat January2025 maybe the momth after
it went parabolic It's almost I feel doing
the samething. N 83% chance the etf is getting approved I read so I compare it to bitcoin when the inflows n outoutflows started with bitcoin well it will start with xrp' hopefully to be etfs and also I read the sec has to pay xrp or ripple a billion dollars which I think are all good things n indicators thar it's smart to buy now n hold or just hold that's what I'm doing. falling wedge pattern and it's just so viotile it will happen just stay calm an watch as UT goes up n up n up let's all hope for it 🙏
“I want to share my experience with 𝐂𝐚𝐭𝐡𝐞𝐫𝐢𝐧𝐞 𝐄. 𝐑𝐮𝐬𝐬𝐞𝐥𝐥👥Facebook page. Get the edge in crypto trading chat, who has been an exceptional crypto trader. Her trading signals are incredibly accurate, and especially now with Bitcoin soaring, she has helped me generate significant profits. Catherine is honest, trustworthy, and truly committed to her clients’ success. She is not a scam or an imposter—she’s the real deal and genuinely cares about helping people. If you’re considering crypto trading, don’t miss this opportunity. Reach out to her on Facebook and see for yourself!”
Amen to that like Warren buffet says
"when there's blood in the streets buy" he's definitely rite just gotta hold name of the
game...some of the questions I see on
here people really listen to the media then
it's changed an forgotten in ghe news
literally 5 days later not even and
lol its forgotten
The banks make too much money in fees using Swift that's why they're reluctant to adopt xrp cuz they would rather keep ripping people off that want to send cross border payments the old archaic way with Swift but it's coming and you can't stop it you can hold on to your power with Glenn death but as your heart gets weaker and weaker and you get older and older you will no longer have power from the grave and then eventually xrp will be adopted for institutional use your powers stops when they throw the first shovel of dirt on top of your casket
$xrp To the moon 🚀🚀🚀
XRP has once again found support near the $2.1 range, signaling a strong rebound ahead. A powerful surge is imminent, with the next target set at $4
Omg did you make that money??
xrp may bounce to $4 after tariff shits ends
Egrag Crypto’s bold $27 XRP prediction is certainly intriguing! A 7-year symmetrical triangle breakout and a 283% surge make for a compelling technical setup. However, sustained momentum will likely depend on broader market conditions and regulatory developments. Do you think XRP can realistically reach this target?